Inhibrx Biosciences (INBX) EBIT Margin (2023 - 2025)
Inhibrx Biosciences (INBX) posted quarterly EBIT Margin of 2106.85% for Q2 2025, up 15879115.0% year-over-year from N/an in Q2 2024, and up 95.78% quarter-over-quarter from 49928.0% in Q4 2024.
Powered by 
Analysis
Inhibrx Biosciences (INBX) EBIT Margin (2023 - 2025) Analysis & Trends
Inhibrx Biosciences (INBX) has reported EBIT Margin for 3 consecutive years, with 2106.85% the latest figure, recorded in Q2 2025.
- In Q2 2025, EBIT Margin rose 15879115.0% year-over-year to 2106.85%; the TTM figure through Dec 2025 stood at 9644.64% (up 842777.0% YoY), while the FY2025 annual figure was 10386.54%, up 15533746.0% from the prior year.
- EBIT Margin grew to 2106.85% in Q2 2025 per INBX's latest filing, from 49928.0% in the prior quarter.
- Across five years, EBIT Margin topped out at 2106.85% in Q2 2025 and bottomed at 160898.0% in Q2 2024.
- Historically, EBIT Margin has averaged 65773.81% across 3 years, with a median of 44219.04% in 2023.
- Annual changes were most pronounced in 2024 — EBIT Margin plunged 4452476 bps — and 2025, when it soared 15879115 bps.
- Inhibrx Biosciences' EBIT Margin stood at 5403.24% in 2023, then tumbled by 824 bps to 49928.0% in 2024, then jumped by 96 bps to 2106.85% in 2025.
- Business Quant data shows INBX's EBIT Margin at 2106.85% in Q2 2025, 49928.0% in Q4 2024, and 160898.0% in Q2 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 19.75% |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.36% |
| 10 | Inhibrx Biosciences | 1.91 Bn | 1.91 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | -2,106.85% |
| Dec 31, 2024 | -49,928.00% |
| Jun 30, 2024 | -160,898.00% |
| Dec 31, 2023 | -5,403.24% |
| Sep 30, 2023 | -38,510.08% |
| Jun 30, 2023 | -137,796.67% |